Semaglutide 10mg
High-dose GLP-1 receptor agonist for advanced metabolic research.
Tap a strength to switch — price, image & stock update automatically
Key Benefits
15–20% body weight loss demonstrated in clinical trials
potent insulin secretagogue with glucagon suppression
26% reduction in MACE in SUSTAIN-6 trial
central CNS action reduces caloric intake
Active Signaling Pathway
Investigated Pathways
Proposed Mechanism
Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to native GLP-1. Its C18 fatty acid chain enables albumin binding, extending half-life to ~7 days. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally to reduce appetite.
Research Highlights
- SUSTAIN and STEP clinical trial programs demonstrated 15–20% body weight reduction
- Shown to reduce major adverse cardiovascular events (MACE) by 26% in SUSTAIN-6
- FDA-approved for type 2 diabetes (Ozempic) and obesity (Wegovy)
- Demonstrated neuroprotective effects in Parkinson's disease research
Evidence is primarily from in vitro cell studies and animal models. Human data is limited or absent.
For laboratory research only
All Research Systems →Human Body
Research begins at the whole-organism level — studying systemic metabolic markers, energy expenditure, and physiological response to peptide intervention.
For laboratory research and educational purposes only.
Human Body
Research begins at the whole-organism level — studying systemic metabolic markers, energy expenditure, and physiological response to peptide intervention.
For laboratory research and educational purposes only.
For research use only — not for human consumption. No treatment claims.
Full Research Hub →Recommended Stacks
Semaglutide 10mg is a key compound in these curated research stacks. Pair it with synergistic peptides for enhanced outcomes.
CagriSema Metabolic Protocol
GLP-1 + amylin combination — replicating the most potent pharmacological weight loss approach in Phase 3 trials.
How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 10mg vial — and when to plan your next order.
Vial supply estimate is based on standard research protocol volumes. Actual duration will vary based on your specific protocol design.
Scientific Background
Mechanism of Action
Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to native GLP-1. Its C18 fatty acid chain enables albumin binding, extending half-life to ~7 days. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and acts centrally to reduce appetite.
Clinical Context
Semaglutide represents the current gold standard in GLP-1 receptor agonist research. The 10mg vial format supports extended research protocols or multi-subject studies.
Research Highlights
- SUSTAIN and STEP clinical trial programs demonstrated 15–20% body weight reduction
- Shown to reduce major adverse cardiovascular events (MACE) by 26% in SUSTAIN-6
- FDA-approved for type 2 diabetes (Ozempic) and obesity (Wegovy)
- Demonstrated neuroprotective effects in Parkinson's disease research
Storage & Reconstitution
Key Studies
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Wilding JPH et al.
Semaglutide 2.4 mg/week produced 14.9% mean body weight reduction vs 2.4% placebo over 68 weeks.
PubMed →Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
Marso SP et al.
Semaglutide reduced major adverse cardiovascular events by 26% vs placebo in high-risk T2D patients.
PubMed →Neuroprotective effects of semaglutide in Parkinson's disease
Athauda D et al.
GLP-1 receptor agonism demonstrated neuroprotective effects in Parkinson's disease models and a Phase 2 clinical trial.
PubMed →Pharmacokinetics
Bioavailability indicates how much of the compound reaches systemic circulation. Peak plasma is when blood levels are highest. Half-life determines dosing frequency — compounds with short half-lives require more frequent dosing to maintain therapeutic levels.
The volume of distribution reflects how widely the compound distributes into tissues. A higher Vd means the compound concentrates in tissues rather than staying in plasma.
Receptor Binding Profile
Activates cAMP/PKA signaling in pancreatic β-cells, hypothalamus, and gut
Reduces hunger signaling via arcuate nucleus GLP-1R activation
Glucose-dependent insulin secretion and glucagon suppression
Delays gastric emptying, prolonging satiety
Side Effects & Adverse Events
- Nausea (44%)
- Vomiting (24%)
- Diarrhea (30%)
- Constipation (24%)
- Injection site reactions
- Fatigue
- Dizziness
- Pancreatitis (rare)
- Gallbladder disease
- Thyroid C-cell tumors (rodent data)
Contraindications & Interactions
Synergistic Compounds
CagriSema combination shows additive weight loss up to 25% — complementary GLP-1 and amylin receptor mechanisms.
Semaglutide 2.4 mg + Cagrilintide 2.4 mg, both once weekly SubQ.
View Compound →Lipo-C provides B12 repletion and lipotropic support during GLP-1 caloric restriction.
Lipo-C 1 mL IM 2–3× per week alongside weekly semaglutide injection.
View Compound →Transparent Global Sourcing
Manufactured
Sourced through our manufacturing partner in China
Independent Testing
Analytical reports available from Janoshik Analytical
Batch Verification
Batch-specific COAs with online verification via janoshik.com
US Fulfillment
Orders fulfilled from the United States